Drug Overview

SiG12D LODER is a cutting-edge, experimental cancer treatment designed to attack one of the most difficult targets in oncology: the mutated KRAS gene. This drug represents a new frontier in precision medicine, using a specialized delivery system to get the treatment exactly where it is needed. It is a prime example of a Targeted Therapy and is often referred to as a “Smart Drug” because it seeks out a specific genetic mistake that causes tumors to grow.

This medication is currently being studied in international clinical trials, particularly for patients with pancreatic cancer. Because it is an investigational biological agent, it is only available to patients who are enrolled in approved medical research programs.

• Generic name: SiG12D LODER (also known as siG12D-LODER)
• US Brand names: None (Investigational drug)
• Drug Class: siRNA (Small Interfering RNA), KRAS inhibitor
• Route of Administration: Intratumoral (injected directly into the tumor)
• FDA Approval Status: Investigational (Granted Orphan Drug Designation for pancreatic cancer)

What Is It and How Does It Work? (Mechanism of Action)

SiG12D LODER is a unique Targeted Therapy that uses “gene silencing” to stop cancer. To understand how it works at the molecular level, we must look at the instructions inside a cancer cell.

In many types of cancer, especially pancreatic cancer, a gene called KRAS is broken. This specific mutation is called KRAS G12D. When this gene is mutated, it acts like a broken light switch that is permanently stuck in the “on” position. This sends a non-stop signal through communication pathways like the MAPK and PI3K pathways, telling the cell to divide and grow without stopping.

The drug consists of two main parts:

1. siRNA (Small Interfering RNA): This is the “active” ingredient. It is a tiny piece of genetic material designed to match the mutated KRAS G12D instructions exactly.
2. LODER (Local Drug Eluter): This is a tiny, biodegradable shield (a polymer matrix) that protects the siRNA.

When the LODER is placed directly into the tumor, it slowly dissolves over several months. As it dissolves, it releases the siRNA. The siRNA enters the cancer cells and finds the “messenger” molecules carrying the broken KRAS instructions. The siRNA binds to these messengers and destroys them before they can be used to make proteins. This is called “gene silencing.” Without those instructions, the growth signals are cut off, the MAPK and PI3K pathways are shut down, and the cancer cell can no longer survive or multiply.

FDA Approved Clinical Indications

Because SiG12D LODER is an investigational drug, it does not currently have official FDA-approved uses for the general public. It is being studied in clinical trials for the following:

Oncological uses

• Investigational treatment for locally advanced, non-resectable pancreatic cancer (in combination with chemotherapy).
• Investigational research into other solid tumors that carry the KRAS G12D mutation.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, SiG12D LODER is not a pill or a standard IV drip. It is a “mini-scaffold” that is placed directly into the tumor by a specialist doctor using a needle guided by an ultrasound.

Dose Adjustments

Because this drug is placed directly into the tumor and is not processed by the liver or kidneys in the same way as traditional drugs, standard dose adjustments for renal or hepatic insufficiency are not currently established. However, the patient’s overall health and the size of the tumor are used to determine if they are a good candidate for the procedure.

Clinical Efficacy and Research Results

Clinical research data from the 2020 to 2025 period have focused on the PROPEL Phase 2 study. This study looks at patients with pancreatic cancer who receive SiG12D LODER alongside standard chemotherapy (Gemcitabine and Nab-paclitaxel).

Numerical data from these trials show that the treatment is very promising. In early reports, the combination of the LODER and chemotherapy resulted in a “Disease Control Rate” of approximately 77 percent to 80 percent. This means that for the majority of patients, the tumor either shrank or stopped growing. Furthermore, some patients who were previously told their tumors were “unresectable” (cannot be removed by surgery) saw enough tumor shrinkage that they were able to undergo successful surgery. While overall survival data is still being collected, the ability to turn a non-operable tumor into an operable one is considered a significant success in pancreatic cancer research.

Safety Profile and Side Effects

SiG12D LODER has a safety profile that is divided between the drug itself and the medical procedure used to place it.

Black Box Warning

There is no official FDA Black Box Warning for SiG12D LODER because it is an investigational drug.

Common side effects

These occur in more than 10 percent of patients (often related to the accompanying chemotherapy):

• Abdominal pain or discomfort
• Nausea and vomiting
• Feeling very tired (fatigue)
• Fever
• Low white blood cell counts

Serious adverse events

• Pancreatitis (inflammation of the pancreas caused by the injection procedure)
• Infection at the injection site
• Internal bleeding or perforation during the ultrasound procedure
• Severe allergic reactions to the drug materials

Management strategies

To manage the risks of the procedure, patients are often given antibiotics and pain medication. Because the drug is released slowly over 12 weeks, most “drug-related” side effects are mild. The medical team uses frequent imaging (CT scans) and blood tests to monitor the pancreas for any signs of inflammation.

Research Areas

SiG12D LODER is at the center of Research Areas involving “Metabolic Reprogramming” and “Tumor Microenvironment.” Mutated KRAS is known to help cancer cells hide from the immune system. Researchers are studying whether silencing KRAS with the LODER makes the tumor more “visible” to the immune system. There is also active research into combining this drug with Immunotherapy (like Pembrolizumab) to see if the two “Smart Drugs” together can create a more permanent defense against the cancer.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Biopsy and genetic testing to confirm the KRAS G12D mutation.
• Imaging (CT scan or MRI) to measure the exact size and location of the tumor.
• Blood tests for liver and kidney function, as well as blood clotting ability.

Precautions during treatment

Because this treatment involves a medical procedure (Endoscopic Ultrasound), patients must follow standard surgical precautions, such as not eating or drinking for several hours before the procedure.

Do’s and Don’ts list

• Do report any sudden or severe stomach pain to your care team immediately.
• Do keep all follow-up appointments for CT scans to monitor the LODER.
• Do stay hydrated and follow the dietary advice given by your oncology nutritionist.
• Don’t ignore a fever, as it could be a sign of infection following the procedure.
• Don’t stop your standard chemotherapy unless your doctor tells you to, as the LODER is meant to work with it.
• Don’t take any new herbal supplements without asking your research doctor, as they may interfere with your blood’s ability to clot.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. SiG12D LODER is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.